NORTHWEST BIOTHERAPEUTICS INC NWBO
NORTHWEST BIOTHERAPEUTICS INC statistics & valuation
Market cap$304.0M
Net margin-4365.9%
FCF margin-3357.5%
Net debt$57.0M
Enterprise value USD$361.0M
Earnings yield EBIT/EV-16.6%
Market cap as of 2026-06-30. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -4347.9% | -4812.4% | -2873.1% | -3991.7% | -5244.0% | -6708.4% | -1161.0% | -10068.2% | -16273.2% | -12723.3% |
| Net margin | -4365.9% | -6062.1% | -3240.1% | -6240.8% | 17823.5% | -41039.6% | -863.6% | -8687.9% | -21768.8% | -12875.4% |
| FCF margin | -3357.5% | -4199.1% | — | — | — | — | -1329.0% | — | — | — |
| Return on assets | -74.0% | -313.4% | -224.7% | -335.3% | 446.0% | -1610.4% | -195.5% | -145.1% | -149.6% | -151.6% |
| Return on equity | 99.8% | 88.7% | 95.2% | 82.0% | -144.5% | 146.0% | 46.2% | 74.4% | 108.6% | 302.7% |
| Debt / equity | -1.00× | -0.66× | -0.62× | -0.17× | -0.26× | -0.04× | -0.28× | -0.35× | -0.47× | -1.20× |
| Current ratio | 0.06 | 0.06 | 0.09 | 0.07 | 0.13 | 0.04 | 0.07 | 0.34 | 0.02 | 0.10 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.